Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.

Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretić L, Lim D, Wang L, Chen Z, Chen X, Lu P, Paik PK, Shen R, Jin H, Buettner R, Ansén S, Perner S, Brockmann M, Bos M, Wolf J, Gardizi M, Wright GM, Solomon B, Russell PA, Rogers TM, Suehara Y, Red-Brewer M, Tieu R, de Stanchina E, Wang Q, Zhao Z, Johnson DH, Horn L, Wong KK, Thomas RK, Ladanyi M, Pao W
Nat Med. 2014 20 (9): 1027-34

PMID: 25173427 · PMCID: PMC4159407 · DOI:10.1038/nm.3667

MeSH Terms (13)

Anaplastic Lymphoma Kinase Crizotinib Female Gene Knockdown Techniques Humans Insulin Receptor Substrate Proteins Lung Neoplasms Middle Aged Pyrazoles Pyridines Receptor, IGF Type 1 Receptor Protein-Tyrosine Kinases Up-Regulation

Connections (2)

This publication is referenced by other Labnodes entities:

Links